Lectin expression in Cystic Fibrosis

  • Research type

    Research Study

  • Full title

    Contribution of Lectin Receptors to the pathogenesis of Pseudomonas aeruginosa (PA) in the context of Cystic Fibrosis

  • IRAS ID

    190057

  • Contact name

    Luisa Martinez-Pomares

  • Contact email

    luisa.m@nottingham.ac.uk

  • Sponsor organisation

    University of Nottingham

  • Duration of Study in the UK

    2 years, 9 months, 2 days

  • Research summary

    Lectin receptors are receptors present in immune cells that bind sugars. Some of these lectin receptors, like DC-SIGN and mannose receptor, do not directly activate the immune system. In particular DC-SIGN has been shown to act as an inhibitor of immunity. It is plausible to expect that by engaging DC-SIGN, bacteria can promote ineffective immune responses that result in persistent chronic bacterial infections and inflammation that damage the host. An scenario observed in persons with Cystic Fibrosis; particularly those infected with the bacterium Pseudomonas aeruginosa (PA). Infection with PA is especially troublesome in Cystic Fibrosis where it is a major determinant of the irreversible loss of lung function and mortality.

    • We have found that PA produce sugars that can bind to DC-SIGN and mannose receptor. Based on these results we suggest that by binding DC-SIGN and mannose receptor, PA makes the immune response less effective in clearing this bacteria.

    • In this study we aim to:
    o (1) Compare the expression of lectin receptors, such as DC-SIGN and mannose receptor, in immune cells of persons with Cystic Fibrosis and control individuals. This will help us to establish if these receptors could indeed contribute to the recognition of PA infection by the immune system and if they are differentially regulated in persons with Cystic Fibrosis compared to non-Cystic Fibrosis donors.

    o (2) We will also determine potential links between levels of expression of lectin receptors and clinical characteristics in persons with Cystic Fibrosis which could provide a novel tool to gauge disease progression.

  • REC name

    London - Dulwich Research Ethics Committee

  • REC reference

    17/LO/1117

  • Date of REC Opinion

    21 Jul 2017

  • REC opinion

    Further Information Favourable Opinion